Vincent Lanteri, MD
Urology · Long Branch, NJNPI 1528036670
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations.
Across 56 payments — averaging $44.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$568
- Johnson & Johnson$427
- Kerecis Limited$297
- Astellas Pharma US Inc$159
- Immunitybio, Inc.$154
- Teleflex LLC$125
- plus $735 from 17 others
Across 5 payments — averaging $50,000 each. An ownership or investment interest held by the physician or an immediate family member.
- New Wave Endo-surgical Corp.$250K
What the payments were for
- Food & beverage$2,35395%
- Education$1115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 5 | $568 |
| Johnson & Johnson(2 entities) | 4 | $427 |
| Kerecis Limited | 3 | $297 |
| Astellas Pharma US Inc | 5 | $159 |
| Immunitybio, Inc. | 1 | $154 |
| Teleflex LLC | 1 | $125 |
| Urogen Pharma, Inc. | 2 | $110 |
| Sumitomo Pharma America, Inc. | 1 | $108 |
| Boston Scientific | 4 | $76 |
| Bayer | 4 | $68 |
| Tolmar Pharmaceuticals, Inc. | 4 | $55 |
| Myovant Sciences Inc. | 3 | $45 |
| Endo Pharmaceuticals Inc. | 3 | $42 |
| 180 Medical, Inc. | 2 | $33 |
| Tolmar, Inc. | 2 | $31 |
| Ferring Pharmaceuticals Inc. | 2 | $27 |
| Pfizer | 2 | $26 |
| AbbVie | 2 | $25 |
| Metuchen Pharmaceuticals | 2 | $23 |
| Olympus America Inc. | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| Urovant Sciences Inc | 1 | $15 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$980
- AquaBeam Robotic System$523
- STRATAFIX$271
- Kerecis Omega3 SurgiClose$245
- SURGICEL NU-KNIT$154
- Echelon Flex$154
- ANKTIVA$154
- RYBREVANT$143
- CARVYKTI$143
- UroLift$125
- VISTASEAL$117
- GEMTESA$108
How this compares
$2,465 in reported general payments places this provider in the 55th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 22 | $25,714 |
| MyrbetriqMirabegron | 16 | $12,650 |
| Tamsulosin Hcl | 633 | $12,028 |
| Finasteride | 284 | $5,817 |
| Tadalafil | 74 | $3,164 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 93 | $2,495 |
| Testosterone | 19 | $2,304 |
| Oxybutynin Chloride | 52 | $1,038 |
| Oxybutynin Chloride ErOxybutynin Chloride | 24 | $1,018 |
| NitrofurantoinNitrofurantoin Macrocrystal | 20 | $687 |
| Trimethoprim | 14 | $687 |
| Bicalutamide | 12 | $634 |
| Ciprofloxacin Hcl | 70 | $394 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 15 | $372 |
| Allopurinol | 26 | $338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $108 | $25,71422 claims |
| Astellas Pharma US IncMyrbetriq | $159 | $12,65016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 401 urology providers in New Jersey.
Other urology in Long Branch
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
- Robert SimonCliffside Park$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.